Weller J - Search Results

1

Glycolysis and the pentose phosphate pathway are differentially associated with the dichotomous regulation of glioblastoma cell migration versus proliferation.

Kathagen-Buhmann A, Schulte A, Weller J, Holz M, Herold-Mende C, Glass R, Lamszus K. Kathagen-Buhmann A, et al. Among authors: weller j. Neuro Oncol. 2016 Sep;18(9):1219-29. doi: 10.1093/neuonc/now024. Epub 2016 Feb 24. Neuro Oncol. 2016. PMID: 26917237 Free PMC article.

2

The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have anti-proliferative effects.

Kathagen-Buhmann A, Maire CL, Weller J, Schulte A, Matschke J, Holz M, Ligon KL, Glatzel M, Westphal M, Lamszus K. Kathagen-Buhmann A, et al. Among authors: weller j. Neuro Oncol. 2018 Nov 12;20(12):1594-1605. doi: 10.1093/neuonc/noy117. Neuro Oncol. 2018. PMID: 30053149 Free PMC article.

3

PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.

Weller J, Katzendobler S, Karschnia P, Lietke S, Egensperger R, Thon N, Weller M, Suchorska B, Tonn JC. Weller J, et al. Among authors: weller m. J Neurooncol. 2021 Jun;153(2):283-291. doi: 10.1007/s11060-021-03765-z. Epub 2021 May 1. J Neurooncol. 2021. PMID: 33932195 Free PMC article.

4

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?

Teske N, Karschnia P, Weller J, Siller S, Dorostkar MM, Herms J, von Baumgarten L, Tonn JC, Thon N. Teske N, et al. Among authors: weller j. J Neurooncol. 2022 Jan;156(2):317-327. doi: 10.1007/s11060-021-03912-6. Epub 2021 Dec 13. J Neurooncol. 2022. PMID: 34902093 Free PMC article.

5

Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3.

Weller J, Katzendobler S, Blobner J, Thiele F, Becker H, Quach S, Egensperger R, Niyazi M, Suchorska B, Thon N, Weller M, Tonn JC. Weller J, et al. Among authors: weller m. J Neurooncol. 2022 Oct;160(1):149-158. doi: 10.1007/s11060-022-04128-y. Epub 2022 Sep 16. J Neurooncol. 2022. PMID: 36112301 Free PMC article.

6

Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status.

Weller J, Katzendobler S, Niedermeyer S, Harter PN, Herms J, Trumm C, Niyazi M, Thon N, Tonn JC, Stoecklein VM. Weller J, et al. J Neurooncol. 2023 Jun;163(2):407-415. doi: 10.1007/s11060-023-04362-y. Epub 2023 Jun 8. J Neurooncol. 2023. PMID: 37289281 Free PMC article.

7

The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine.

Katzendobler S, Do A, Weller J, Rejeski K, Dorostkar MM, Albert NL, Forbrig R, Niyazi M, Egensperger R, Tonn JC, von Baumgarten L, Quach S, Thon N. Katzendobler S, et al. Among authors: weller j. Front Oncol. 2022 Dec 20;12:1014711. doi: 10.3389/fonc.2022.1014711. eCollection 2022. Front Oncol. 2022. PMID: 36605448 Free PMC article.

8

Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma.

Blobner J, Dengler L, Blobner S, Eberle C, Weller J, Teske N, Karschnia P, Rühlmann K, Heinrich K, Ziemann F, Greif PA, Jeremias I, Wuerstlein R, Hasselmann K, Dorostkar M, Harter PN, Quach S, Stoecklein V, Albert NL, Niyazi M, Tonn JC, Thon N, Christoph Westphalen B, von Baumgarten L. Blobner J, et al. Among authors: weller j. Neurooncol Adv. 2023 May 12;5(1):vdad060. doi: 10.1093/noajnl/vdad060. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37287694 Free PMC article.

9

Prognostic value of O-(2-[¹⁸F]-fluoroethyl)-L-tyrosine PET in relapsing oligodendroglioma.

Schneider F, Wolpert F, Stolzmann P, Albatly AA, Kenkel D, Weller J, Weller M, Kollias SS, Rushing EJ, Veit-Haibach P, Huellner MW. Schneider F, et al. Among authors: weller m, weller j. Acta Oncol. 2020 Nov;59(11):1357-1364. doi: 10.1080/0284186X.2020.1787507. Epub 2020 Jul 20. Acta Oncol. 2020. PMID: 32686979

10

MRI and ¹⁸FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial.

Wirsching HG, Roelcke U, Weller J, Hundsberger T, Hottinger AF, von Moos R, Caparrotti F, Conen K, Remonda L, Roth P, Ochsenbein A, Tabatabai G, Weller M. Wirsching HG, et al. Among authors: weller m, weller j. Clin Cancer Res. 2021 Jan 1;27(1):179-188. doi: 10.1158/1078-0432.CCR-20-2096. Epub 2020 Sep 23. Clin Cancer Res. 2021. PMID: 32967939 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

836 results

Search Page